Journal: mAbs

Article Title: Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics

doi: 10.1080/19420862.2018.1538723

Figure Lengend Snippet: Details on generation and affinity of Type 3 and 4 antibodies used in this study.

Article Snippet: Detection was performed with HRP-conjugated Type 3 antibody AbD29928 (Bio-Rad HCA304) in HISPEC assay diluent.

Techniques: Blocking Assay

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Table of study acronyms

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques: Injection, Inhibition

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Treatment groups in included trials

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques: Injection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Summary of findings: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Summary of findings: anti‐VEGF treatment versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 1 year: ranibizumab versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 2 years: ranibizumab versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 5 Visual acuity better than 20/200 at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 6 Visual acuity better than 20/200 at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 7 Mean change in visual acuity at 1 year (number of letters).

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 8 Mean change in visual acuity at 2 years (number of letters).

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 9 Reduction in central retinal thickness at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 10 Reduction in central retinal thickness at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 11 No problems in quality of life domain at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 12 No problems in quality of life domain at 2 years.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 1 year: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Adverse events up to 2 years: bevacizumab versus ranibizumab

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Comparison 2 Bevacizumab versus ranibizumab, Outcome 13 Loss of fewer than 30 letters visual acuity at 1 year.

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration

doi: 10.1002/14651858.CD005139.pub4

Figure Lengend Snippet: Anti‐VEGF treatment versus control

Article Snippet: Notes , Full study name: Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration Trial registration: {"type":"clinical-trial","attrs":{"text":"NCT00056836","term_id":"NCT00056836"}} NCT00056836 Funding sources: Genentech, USA, and Novartis Pharma, Switzerland Declarations of interest: various authors reported that they had received consulting fees from Genentech, Eyetech, Novartis Ophthalmics, Novartis, QLT, Alcon Laboratories, Pfizer, Regeneron, Theragenics, VisionCare, Protein Design Labs, Allergan, BioAxone, Tanox, Genaera, Jerini, Oxigene, Quark, Genzyme, iScience, ISTA, and Athenagen; lecture fees from Genentech, Eyetech, Pfizer, Jerini, Allergan, and Novartis Ophthalmics; grant support from Genentech, Novartis, Eyetech, Pfizer, Theragenics, and Genaera and Alcon Laboratories; and/or equity interest in Pfizer and/or were employees of Genentech and owned Genentech stock Study period: enrollment March 2003 to December 2003 Reported subgroup analyses: by baseline lesion (4 or fewer optic disc areas; more than 4), type of lesion (minimally classic; occult with no classic), and baseline VA (fewer than 55 letters; 55 or more letters) Contacting study investigators: trial authors contacted and contributed information for this review , .

Techniques:

Journal: Medicina

Article Title: Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema

doi: 10.3390/medicina59061053

Figure Lengend Snippet: Correlation between relative flow volume in main vessel and branch vessels 1 and 2 before intravitreal ranibizumab injection ( A ) Before intravitreal ranibizumab injection (IRI), relative flow volume (RFV) in the main artery in the non-occluded region correlated significantly with the summed RFV in branch arteries 1 and 2 (r = 0.93, p < 0.001). ( B ) Before IRI, RFV in the main vein in the non-occluded region correlated significantly with the summed RFV in branch veins 1 and 2 (r = 0.85, p < 0.001). ( C ) Before IRI, RFV in the main artery in the occluded region correlated significantly with the summed RFV in branch arteries 1 and 2 (r = 0.81, p < 0.001). ( D ) Before IRI, RFV in the main vein in the occluded region correlated significantly with the summed RFV in branch veins 1 and 2 (r = 0.93, p < 0.001).

Article Snippet: We enrolled 37 patients with BRVO (37 eyes) who were to be treated by IRI (Lucentis; 0.5 mg in 0.05 mL; Genentech, Inc., South San Francisco, CA, USA) at the Department of Ophthalmology of Tokyo Medical University, Tokyo, Japan, from June 2017 to July 2019.

Techniques: Injection

Journal: Medicina

Article Title: Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema

doi: 10.3390/medicina59061053

Figure Lengend Snippet: Correlation between relative flow volume in main vessel and branch vessels 1 and 2 after intravitreal ranibizumab injection ( A ) After intravitreal ranibizumab injection (IRI), relative flow volume (RFV) in the main artery in the non-occluded region correlated significantly with the summed RFV in branch arteries 1 and 2 (r = 0.88, p < 0.001). ( B ) After IRI, RFV in the main vein in the non-occluded region correlated significantly with the summed RFV in branch veins 1 and 2 (r = 0.80, p < 0.001). ( C ) After IRI, RFV in the main artery in the occluded region correlated significantly with the summed RFV in branch arteries 1 and 2 (r = 0.84, p < 0.001). ( D ) After IRI, RFV in the main vein in the occluded region correlated significantly with the summed RFV in branch veins 1 and 2 (r = 0.92, p < 0.001).

Article Snippet: We enrolled 37 patients with BRVO (37 eyes) who were to be treated by IRI (Lucentis; 0.5 mg in 0.05 mL; Genentech, Inc., South San Francisco, CA, USA) at the Department of Ophthalmology of Tokyo Medical University, Tokyo, Japan, from June 2017 to July 2019.

Techniques: Injection

Journal: Medicina

Article Title: Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema

doi: 10.3390/medicina59061053

Figure Lengend Snippet: Change in relative flow volume from baseline to 1 month after intravitreal ranibizumab injection ( A ) Relative flow volume (RFV) of the main artery and branch arteries 1 and 2 in the non-occluded region did not significantly change from baseline (main artery, 243 ± 88.3 AU; branch artery 1, 156 ± 72.8 AU; branch artery 2, 120 ± 74.5 AU) to 1 month after intravitreal ranibizumab injection (IRI; main artery, 250 ± 101 AU, p = 0.599; branch artery 1, 153 ± 85.3 AU, p = 0.679; branch artery 2, 113 ± 60.6 AU, p = 0.263). ( B ) RFV in the main vein and branch veins 1 and 2 in the non-occluded region did not significantly change from baseline (main vein, 430 ± 171 AU; branch vein 1, 294 ± 152 AU; branch vein 2, 179 ± 98.7 AU) to 1 month after IRI (main vein, 432 ± 163 AU, p = 0.937; branch vein 1, 284 ± 141 AU, p = 0.560; branch vein 2, 196 ± 135 AU, p = 0.399). ( C ) RFV in the main artery in the occluded region decreased significantly from baseline (242 ± 108 AU) to 1 month after IRI (216 ± 110 AU; p = 0.008), but no significant change from baseline to 1 month after IRI was seen in RFV in branch artery 1 (143 ± 76.9 AU vs. 139 ± 89.5 AU, respectively; p = 0.553) or 2 (104 ± 46.6 AU vs. 98.6 ± 59.3 AU, respectively; p = 0.285). ( D ) RFV in the main vein in the occluded region decreased significantly from baseline to 1 month after IRI (330 ± 140 AU vs. 291 ± 138 AU, respectively; p = 0.026), but no significant change from baseline to 1 month after IRI was seen in RFV in branch vein 1 (220 ± 122 AU vs. 199 ± 118 AU, respectively; p = 0.144) or 2 (133 ± 81.2 AU vs. 119 ± 84.8 AU, respectively; p = 0.095).

Article Snippet: We enrolled 37 patients with BRVO (37 eyes) who were to be treated by IRI (Lucentis; 0.5 mg in 0.05 mL; Genentech, Inc., South San Francisco, CA, USA) at the Department of Ophthalmology of Tokyo Medical University, Tokyo, Japan, from June 2017 to July 2019.

Techniques: Injection

Journal: Medicina

Article Title: Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema

doi: 10.3390/medicina59061053

Figure Lengend Snippet: Change in vessel width from baseline to 1 month after intravitreal ranibizumab injection ( A ) The width of the main artery and branch vessels 1 and 2 in the non-occluded region did not change significantly from baseline (main artery, 12.6 ± 2.12 pixel; branch artery 1, 10.7 ± 2.53 pixel; branch artery 2, 10.5 ± 2.46 pixel) to 1 month after intravitreal ranibizumab injection (IRI; main artery, 12.1 ± 3.32 pixel, p = 0.405; branch artery 1, 10.8 ± 2.26 pixel, p = 0.928; branch artery 2, 10.3 ± 2.54 pixel; p = 0.654). ( B ) The width of the main vein and branch veins 1 and 2 in the non-occluded region did not change significantly from baseline (main vein, 17.9 ± 2.86 pixel; branch vein 1, 15.5 ± 2.82 pixel; branch vein 2, 12.5 ± 3.04 pixel) to 1 month after IRI (main vein, 17.2 ± 2.55 pixel, p = 0.146; branch vein 1, 15.1 ± 3.04 pixel, p = 0.218; branch vein 2, 12.5 ± 2.59 pixel, p = 0.946). ( C ) The width of the main artery and branch arteries 1 and 2 in the occluded region did not change significantly from baseline (main artery, 13.4 ± 2.37 pixel; branch artery 1, 11.8 ± 2.76 pixel; branch artery 2, 10.8 ± 2.99 pixel) to 1 month after IRI (main artery, 13.1 ± 3.16 pixel, p = 0.419; branch artery 1, 12.2 ± 2.91 pixel, p = 0.291; branch artery 2, 10.6 ± 3.09 pixel, p = 0.677). ( D ) The width of the main vein and branch veins 1 and 2 in the occluded region did not change significantly from baseline (main vein, 15.8 ± 3.08 pixel; branch vein 1, 13.6 ± 2.97 pixel; branch vein 2, 12.1 ± 2.98 pixel) to 1 month after IRI (main vein, 15.4 ± 3.04 pixel, p = 0.0.78; branch vein 1, 14.0 ± 3.03 pixel, p = 0.410; branch vein 2, 12.1 ± 3.41 pixel, p = 0.863).

Article Snippet: We enrolled 37 patients with BRVO (37 eyes) who were to be treated by IRI (Lucentis; 0.5 mg in 0.05 mL; Genentech, Inc., South San Francisco, CA, USA) at the Department of Ophthalmology of Tokyo Medical University, Tokyo, Japan, from June 2017 to July 2019.

Techniques: Injection